Navigation Links
IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
Date:4/10/2012

NEW YORK, April 10, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC.PK) announced today that the Company has signed a technology licensing agreement with Stem Cells 21 of Thailand, http://www.StemCells21.com. Stem Cells 21 is led by Dr. Chatchai Sribundit MD, a fellow of the College of Anti-ageing Medicine and a member of the National Olympic Committee and Mr. Paul Collier, the Managing Director for the Stem Cells 21.  They have been in the cellular treatment business for over 11 years in Thailand and have a vast amount of experience.  They run the Absolute Health Integrative Medical Center in Bangkok. In partnership with clinics and hospitals, they manage patient care for foreigners traveling to Thailand for medical care. Their partner laboratories and physicians have developed a range of treatment protocols using either umbilical cord blood-derived adult stem cells or adipose-derived cells, from the patient's own body for a wide variety of progressive and debilitating diseases.

Dr. Steven Victor, Chairman of IntelliCell BioSciences stated, "We are excited to sign this technology licensing agreement in Thailand with Stem Cells 21.  With Dr. Chatchai Sribundit and Mr. Paul Collier's extensive experience in cellular therapy, our technology can be utilized to its fullest potential.  We look forward to working with Stem Cells 21 and the Absolute Health Integrative Medical Center in Bangkok to advance the science of adult autologous vascular cellular therapy in Thailand."

About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (HCT/P's) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to enter into technology licensing agreements that cover a particular international territory or country.

Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contact:
IntelliCell BioSciences, Inc.
Rubenstein Investor Relations
Contact: Tim Clemensen
Email Contact: TClemensen@rubensteinir.com
(212) 843-9337  


'/>"/>
SOURCE IntelliCell BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
2. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
3. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
4. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
5. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
6. Amarillo Biosciences Appoints Dr. Stephen Chen as Chairman and CEO
7. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
8. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
9. Ambit Biosciences to Present at Two Upcoming Investor Conferences
10. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
11. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... , ... August 16, 2017 , ... ... microbe delivery system, announced it has secured $2M in funding from an impressive ... Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar is broadening ...
(Date:8/16/2017)... OXFORD, England , Aug. 16, 2017 /PRNewswire/ ... biotech executive search and leadership development, and Virdis Group, global ... created an exclusive alliance that enables clients to leverage the ... "For our clients here in the ... to a diverse population of leadership talent throughout the US, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Nanomedical Diagnostics ... biotherapeutics development, announces the launch of the new NHS Agile biosensor chip ... binding data for a wide range of molecules, including small and large molecules, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Kenall, a leader in sealed ... stay tightly sealed and perform efficiently for years. The downlights are ideal for ... aren't enough, such as: hospitals; behavioral health facilities; cleanrooms; containment areas; food and ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ... of online age and identity verification solutions, announced today ... Identity Conference 2017, May 15 thru May 17, 2017, ... Building and International Trade Center. Identity ... globe and in today,s quickly evolving digital world, defining ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):